Genomic eligibility
ONCOLOGY
All genomic alterations in eligible genes were reviewed by the MD Anderson Precision Oncology Decision Support (PODS) prior to patient enrollment. Alterations were researched within the published literature for any known effect on function, stability, expression, or therapeutic sensitivity. Alterations were then classified for their functional significance and variant-level actionability, as previously described [